Abstract:Background: Methadone, a full opioid agonist, and buprenorphine, a partial agonist at the opioid receptor, are established first-line medications for opioid maintenance therapy. Transition from methadone to sublingual buprenorphine may precipitate withdrawal and is usually performed only in patients on low dose of methadone (<30-40 mg). Transition from methadone to a novel subcutaneous buprenorphine depot (Buvidal) has not been previously described. Objectives: To test the hypothesis that a rapid transition fr… Show more
“…The optimal tactics for direct transfer from methadone to long-lasting buprenorphine formulations has not been defined. A recent case series of Soyka and Groß (2021) of patients with opioid use disorder in a custodial setting suggests that a rapid transfer from methadone, in part at high dosages, to depot buprenorphine via an initial 4 mg sublingual buprenorphine dose is possible. Microdosing techniques to introduce a patient to depot buprenorphine medication has been recently advocated also by Tay Wee Teck et al (2021) .…”
Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine, a partial agonist at the mu receptor, are first-line medications in opioid maintenance treatment. Transition from methadone to buprenorphine may precipitate withdrawal, and no accepted algorithm for this procedure has been developed. Current treatment strategies recommend transfer from methadone to buprenorphine predominantly in patients at low doses of methadone (30–40 mg/day). There are some reports indicating that transition from higher doses of methadone may be possible. A number of dosing strategies have been proposed to soften withdrawal symptoms and facilitate transfer including use of other opioids or medications and especially microdosing techniques for buprenorphine. The case series and studies available thus far are reviewed.
“…The optimal tactics for direct transfer from methadone to long-lasting buprenorphine formulations has not been defined. A recent case series of Soyka and Groß (2021) of patients with opioid use disorder in a custodial setting suggests that a rapid transfer from methadone, in part at high dosages, to depot buprenorphine via an initial 4 mg sublingual buprenorphine dose is possible. Microdosing techniques to introduce a patient to depot buprenorphine medication has been recently advocated also by Tay Wee Teck et al (2021) .…”
Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine, a partial agonist at the mu receptor, are first-line medications in opioid maintenance treatment. Transition from methadone to buprenorphine may precipitate withdrawal, and no accepted algorithm for this procedure has been developed. Current treatment strategies recommend transfer from methadone to buprenorphine predominantly in patients at low doses of methadone (30–40 mg/day). There are some reports indicating that transition from higher doses of methadone may be possible. A number of dosing strategies have been proposed to soften withdrawal symptoms and facilitate transfer including use of other opioids or medications and especially microdosing techniques for buprenorphine. The case series and studies available thus far are reviewed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.